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SYMPOSIUM
CLINICAL VALUE OF PREDICTIVE
TESTS FOR ADVANCED BREAST
CANCER. E. ENGELSMAN. Netherlands
Cancer Institute, Amsterdam.
Endocrine therapy is known to be of
value to some patients with advanced breast
cancer. The patients who experience re-
mission after endocrine therapy are said to
have hormone dependent tumours. The
survival of patients with hormone dependent
tumours is better than of those with non-
responsive tumours. With different endocrine
measures, remissions can be brought about in
about30% ofthepatients. The qualityofthe
remissions obtained by hormone additive
therapy:oestrogens, androgens,antioestrogens
and corticosteroids can be quite good, but as a
rulethe quality ofthe remissions seen afterthe
ablative procedures like oophorectomy,
adrenalectomy and hypophysectomy is
better.
However, to achieve the 30% of good
remissions, the 70% non-responders have to
pay a heavy price, especially ifthe therapy is
adrenalectomy. The average survival of the
non-responders to adrenalectomy is short.
Any test to predict the response to
endocrine therapy would be most welcome.
Several techniques have been investigated:
measuring the symptom-free interval has
some value; with the famous discriminant
function of Bulbrook and Hayward some
selection is possible; the meaning of the
measurement of steroid sulphate synthesis in
breast cancer tissue is still unclear; the
behaviour of radioactive phosphorus in the
tumour in vivo can possibly give some
information but is not a practical test. The
short-term cultures of breast cancer tissue in
different endocrine environments might be of
practical value. Much work has been done
by Braunsberg's group to show that there is
a correlation between the uptake of radio-
labelled oestradiol by the tumour in vitro and
the response to endocrine therapy, but this
method cannot be made into a routine test.
It seems that with the determination of
oestrogen receptors in the cancer tissue in
vitro, a test has come to hand which can be
used as a routine and has a good predictive
value. The work of Jensen, Gorski, Koren-
man, Jungblut, Wagner, Terenius and others
has made this possible. Jensen demonstrated
a good correlation between the presence of
receptors in breast cancer tissue and a
favourable response to subsequent adrena-
lectomy, Maass showed that the correlation
was also valid for other endocrine treatments.
In our Institute the study of oestrogen
receptors in breast cancer metastases was
facilitated by the circumstances that our
staff work together as a team and that all the
services needed are found under the same
roof: surgery, internal medicine, pathology
and biochemical laboratories. The advanced
breast cancer cases were usually treated
according to clinical trial protocols of the
EORTC Breast Cancer Group; the receptor
determinations were done initially by a
charcoal absortion technique; after the 1972-
EORTC Workshop on Standards for the
assessment of oestrogen receptors the agar
gel-electrophoresis technique was adopted, by
which androgen receptors can also be deter-
mined. Only a few patients in whom the
primary tumour was studied have developed
metastases so far, but the advanced cases
have had different types of endocrine treat-
ment : oophorectomy, oestrogens, antioes-
trogens, androgens. The correlation between
favourable response and presence of receptor
is strong.
In the EORTC Breast Cancer Group
comparable results were achieved by Maass
and Trams in Hamburg, who found 20
remissions in 32 receptor positive cases and
2 remissions in 37 receptor negative cases.
Heuson and Leclerq in Brussels noted 6
remissions in 18 receptor positive cases and 1
remission in 12 receptor negative cases. In
all series the correlation seemed less strong
for nafoxidine (antioestrogen) treatment. In
our own material there is a suggestion that
nafoxidine as the first treatment can produce
remissions, but prevents a second therapy
with oestrogens from being effective. After
a successful first therapy with oestrogens,
nafoxidine could produce a second remission
in several patients and so it might be better
to use nafoxidine in the treatment of ad-
vanced breast cancer only after oestrogens
have been timed. In 3 patients with receptor
negative tumours who had subjective re-
missions with oestrogens or androgens, a new
tumour biopsy, taken after the therapy was
stopped, contained receptors. This finding
suggests that oestrogen receptors can be
induced by hormone treatment. Oestrogen
receptor determinations seem to be useful in
the prediction of response to endocrine
treatment; it is certainly necessary to achieve
more insight into the dynamics of the
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receptor-hormone interaction and its biolo-
gical significance.
PREDICTIVE VALUE OF ACID PHOS-
PHATASE. B. MORGAN. Department of
Chemical Pathology, University of Leeds.
There is increasing interest in the use of
clinical and biochemical data to assess the
probability that a patient has, or will develop,
a particular state. The complexity of these
techniques arises in part because they are
based on many variables measured in each
individual. Yet the aims of these techniques
are identical with the aims of making a single
measurement in each individual. It is these
aims which will be discussed here in relation
to a single variable, namely the serum acid
phosphatase activity, and a single clinical
condition, namely carcinoma of the prostate.
The ideal situation would have been as
follows: (1) Two groups were defined which
were comparable in all ways except that one
group had carcinoma of the prostate gland
(CA) and the other did not (N); (2) There was
a measurement (acid phosphatase) which was
simpler than the techniques used to separate
the initial groups and which had different
values in the groups CA and N; (3) There
was no overlap in the values of X in the
groups CA and N; (4) There was no other
condition which could be confused with
carcinoma of the prostate.
The real life situation is of course far
from this ideal. One fundamental difference
is that there is no complete separation of the
values of serum acid phosphatase (AP) in the
two groups (N and CA). Various changes in
technique have been suggested in order to
diminish this overlap of AP between the
groups. These changes are largely aimed at
improving organ specificity by the choice of
substrate and the addition of isoenzyme
inhibitors (Bodansky, Clin. Chem. 1972, 15,
43; Schwartz, Clin. Chemn., 1973, 19, 10).
While these attempts will no doubt
continue, it seems reasonable to conclude that
in this clinical situation, as in so many others,
a single measurement will not completely
discriminate between the groups and that
overlap of the results will remain.
What is so commonly done in practice is
to define a value (the upper limit of normal)
to assume that values above this will not
occur in healthy persons. The finding of a
high value then " indicates " the presence of
the disorder. This approach is an attempt to
make the situation like the ideal one with
complete discrimination.
However, this approach makes no use of
the information in the absolute value of the
measurement. Thus, the higher the value of
AP, the greater the probability of carcinoma
of the prostate. This probability is rarely
formally defined for a single variable al-
though it is now part of some complex
statistical analyses involving several variables
(Hartz, Clin. Chem., 1973, 19, 113). This
probability function must also take into
account the relative prevalence (probabilities)
of the disorders or states which are being
discriminated.
MULTIPARAMETRIC TESTS IN THE
STUDY OF GASTROINTESTINAL
NEOPLASMS. E. H. COOPER. Department
of Cancer Research, University of Leeds.
Several forms of cancer can be con-
veniently staged into a local growth, exten-
sion into local nodes, direct spread beyond
the organ of origin and distant metastases.
This sequence will have reached various
stages when the patient first presents and
after a variable time interval following the
excision of the primary tumour local recur-
rences or distant metastases may develop. A
team of laboratory workers and clinicians in
the Leeds Region and at the Chester Beatty
Institute, London has been examining the
way in which laboratory tests may aid the
diagnosis in gastrointestinal cancers, in
particular, colorectal cancer. This was
chosen partly in view of our participation in
the MRC trial on the evaluation of carcino-
embryonic antigen (CEA) and partly as the
evolution of colorectal cancer follows reason-
ably well-defined patterns. It soon became
apparent that apart from being able to
distinguish metastatic colorectal cancer in-
volving the liver from various types of
hepatitis and cirrhosis, CEA alone was
unable to discriminate the various stages of
evolution of colorectal cancer. As the liver
is the main site of distant metastasis the
contributions of serum enzyme, known to be
elevated in hepatic metastases, to a dis-
criminant function have been examined.
Gammaglutamyl transpeptidase, leucine
aminopeptidase and alkaline phosphatase